Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,588 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Population Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

NCT00745251
View directory record Official record
Conditions
Sleep Apnea
Interventions
VI-0521, placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
30 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 28, 2026, 8:44 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers Results available

The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.

NCT03696953
View directory record Official record
Conditions
Group B Streptococcus Carrier in Childbirth, Gastrointestinal Symptoms
Interventions
Florajen3
Biological
Lead sponsor
Marquette University
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

NCT04399837
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Auburn Hills, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 2 Interventional

Safety Study of Tecadenoson to Treat Atrial Fibrillation

NCT00713401
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Tecadenoson, Esmolol
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 3 Interventional Results available

Group B Streptococcus Response After Probiotic Exposure

NCT04721912
View directory record Official record
Conditions
Group B Strep Infection
Interventions
Probiotic dietary supplement
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Not applicable Interventional Results available

1/2 A Multi-site Systems Intervention for Unemployed Persons With Social Anxiety

NCT02633267
View directory record Official record
Conditions
Social Anxiety
Interventions
Vocational Services as usual plus Cognitive Behavioral Therapy (CBT), Usual Vocational Services
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Not applicable Interventional Results available

Application of Virtual Reality in Post-Operative Recovery of a Pediatric Scoliosis Patient Population

NCT06101264
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Control, Virtual Reality
Device
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
13 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 1 Interventional

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

NCT02599714
View directory record Official record
Conditions
Advanced and Metastatic Breast Cancer
Interventions
AZD2014, Palbociclib, Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
5
States / cities
Encinitas, California • Sarasota, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 28, 2026, 8:44 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
KarXT, KarX-EC, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Long Beach, California • Redlands, California • Basalt, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 8:44 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

NCT04904549
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), Placebo, SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination, SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
23,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Huntsville, Alabama • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 28, 2026, 8:44 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

NCT00184548
View directory record Official record
Conditions
Acquired Bleeding Disorder, Trauma
Interventions
eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 28, 2026, 8:44 PM EDT
Withdrawn Phase 3 Interventional

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

NCT01755247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 28, 2026, 8:44 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
IVT GBS-06, Placebo
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
Other · Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Robustness and Usability of the Dreem 3 System for at Home Sleep Monitoring in an Insomnia Population.

NCT05611099
View directory record Official record
Conditions
Insomnia, Secondary, Sleep Disturbance, Sleep, Sleep Initiation and Maintenance Disorders
Interventions
Dreem 3 System vs WatchPAT One, Usability Questionnaire
Device · Other
Lead sponsor
Dreem
Industry
Eligibility
22 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 28, 2026, 8:44 PM EDT
Recruiting Phase 2 Interventional

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07491458
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
HU6, Placebo
Drug · Other
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

NCT00656578
View directory record Official record
Conditions
Pain
Interventions
4975, Placebo
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Bakersfield, California • Owings Mills, Maryland • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine

NCT02270944
View directory record Official record
Conditions
Infections, Streptococcal, Streptococcal Infections
Interventions
GBS Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Redding, California • Lenexa, Kansas • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 28, 2026, 8:44 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244
View directory record Official record
Conditions
Healthy
Interventions
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix
Biological
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 49 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
119
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia

NCT00497809
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
AVI-014 versus Filgrastim
Drug
Lead sponsor
AviGenics
Industry
Eligibility
18 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Anaheim, California • Greenbrae, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 28, 2026, 8:44 PM EDT
Active, not recruiting Not applicable Interventional

DBT Skills Groups for Veterans at High Risk for Suicide Attempt

NCT05000749
View directory record Official record
Conditions
Suicide, Attempted
Interventions
DBT-SG, VHA treatment as usual
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
San Diego, California • West Haven, Connecticut • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

NCT02372799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 28, 2026, 8:44 PM EDT
Completed Phase 2 Interventional Results available

AZD7268 Safety and Tolerability Study

NCT01020799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD7268, Escitalopram, Placebo capsules, Placebo tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 28, 2026, 8:44 PM EDT